MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
VTRS stock logo

VTRS

Viatris Inc.

$13.44
-0.19
 (-1.39%)
Exchange:  NASDAQ
Market Cap:  15.48B
Shares Outstanding:  244.886M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Scott Andrew Smith
Full Time Employees:  32000
Address: 
1000 Mylan Boulevard
Canonsburg
PA
15317
US
Website:  https://www.viatris.com
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/08 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,426,90014,739,30014,299,900
Gross Profit6,438,6005,623,6005,013,500
EBITDA3,516,5002,820,000-395,400
Operating Income766,20010,100-2,663,100
Net Income54,700-634,200-3,514,900

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets47,685,50041,500,90037,193,100
Total Liabilities27,218,10022,865,40022,481,800
Total Stockholders Equity20,467,40018,635,50014,711,300
Total Debt18,371,20014,305,90014,413,900
Cash and Cash Equivalents991,900734,8001,322,400

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,799,6002,302,9002,315,900
Capital Expenditure-474,500-326,000-378,800
Free Cash Flow2,325,1001,976,9001,937,100
Net Income54,700-634,200-3,514,900
Net Change in Cash-268,900-257,500611,900

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)14,782,238.709Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)15,111,946.594Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)14,971,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)3,067,541.397Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)3,135,960.843Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)3,106,712.262Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)4,071,638.574Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)4,162,453.732Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)4,123,631.223Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)0Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
14.71B  ?P/S
 (TTM)
: 
1.18
?Net Income
 (TTM)
: 
-634200000  ?P/E
 (TTM)
: 
-4.81
?Enterprise Value
 (TTM)
: 
30.256B  ?EV/FCF
 (TTM)
: 
16.62
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
-0.16
?ROE
 (TTM)
: 
-0.23  ?ROIC
 (TTM)
: 
-0.08
?Net Debt
 (TTM)
: 
13.484B  ?Debt/Equity
 (TTM)
: 
1
?P/B
 (TTM)
: 
1.15  ?Current Ratio
 (TTM)
: 
1.3

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
5.46Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates VTRS intrinsic value between $23.54 – $24.38 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate VTRS Intrinsic Value

Common questions about VTRS valuation

Is Viatris Inc. (VTRS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Viatris Inc. (VTRS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is VTRS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VTRS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is VTRS’s P/E ratio?

You can see VTRS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for VTRS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is VTRS a good long-term investment?

Whether VTRS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

VTRS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.39
MARKETSnap

Trading Metrics:

Open: 13.42   Previous Close: 13.63
Day Low: 13.28   Day High: 13.64
Year Low: 6.85   Year High: 16.47
Price Avg 50: 14.3   Price Avg 200: 11.37
Volume: 5.564M   Average Volume: 10.157M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
25-03-2026 19:15
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
26-02-2026 17:08
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
26-02-2026 12:46
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
Viatris forecasts 2026 profit below estimates on India manufacturing woes
26-02-2026 08:37
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
20-02-2026 08:52
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
03-02-2026 16:34
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read